Article info
Commentary
How should randomized controlled trials in epithelial ovarian cancer be interpreted?
- Correspondence to Professor Anna Fagotti, Department of Woman’s and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; anna.fagotti{at}policlinicogemelli.it
Citation
How should randomized controlled trials in epithelial ovarian cancer be interpreted?
Publication history
- Received March 15, 2022
- Accepted March 18, 2022
- First published March 31, 2022.
Online issue publication
November 15, 2022
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.